Aviva Systems Biology

Aviva Systems Biology has been supporting life science research since 2002, with headquarters in San Diego, California. With a portfolio spanning 500,000+ products, Aviva delivers high-quality antibodies, recombinant proteins, and immunoassays, backed by deep expertise in antibody and protein production.

Aviva’s core product range includes:

• ELISA Kits
• Polyclonal Antibodies
• Primary Antibodies
• Monoclonal Antibodies
• Recombinant Monoclonal Antibodies
• Secondary Antibodies
• Recombinant Proteins
• Western Blot–validated antibodies

This wide range allows researchers to source consistent, application-ready reagents from discovery through validation.

Enhanced Validation Polyclonal Antibodies from Aviva Systems Biology

Antibodies are essential for molecular/cellular research but the quality of those reagents can make or break an experiment. Aviva Systems Biology’s Enhanced Validation Polyclonal Antibodies are designed to give researchers confidence in specificity, reproducibility, and performance with the goal of saving valuable time and reducing costly troubleshooting.

Through taking steps beyond the industry norm for antibody validation, Aviva incorporates a multi-layer structure of rigorous testing before an antibody reaches any researchers bench. Overall improving reliability in common applications like Western blotting, immunohistochemistry , immunoprecipitation, and ELISA but also aligning with emerging standards for reproducible antibody-based research. 

What “Enhanced Validation” Actually Means

Rather than relying solely on minimal quality control, Aviva applies several advanced validation methods to its Enhanced Validation Polyclonals:

•  Comprehensive Western Blot Panels: Each antibody is tested across multiple species and tissue samples to demonstrate clear target detection and band specificity. These blot panels help you assess expression patterns in relevant biological contexts. 
  • Surface Plasmon Resonance (SPR) Affinity Characterisation : SPR provides real-time, quantitative data on how strongly an antibody binds to its target. This kinetic profile helps researchers understand and trust the antibody’s performance before experimental use. 
  • Independent Validation via YCharOS Consortium: Aviva participates in the open-source YCharOS initiative, where antibodies are tested in CRISPR knockout cell lines and other standardised systems. This independent evaluation helps ensure that signal loss correlates with gene absence resulting in a powerful demonstration of specificity. 

Beyond these methods, Aviva’s Enhanced Validation program supports independent recognition where more than one antibody against the same target yields consistent results  offering an additional check against non-specificity. 

Because of this multi-layered validation, researchers can trust these antibodies to generate cleaner data, fewer false positives, and better reproducibility across experimental workflows.

High-Sensitivity Tau ELISAs for Neurodegenerative Disease Research

Researching neurodegenerative disease requires tools that can understand the biology as it unfolds: early, dynamically, and at very low signal levels. Among the most informative biomarkers is Tau proteins, particularly Total Tau and phosphorylated Tau species, which reflect neuronal injury, disease progression and pathological signalling long before structural changes become apparent.

As research moves toward earlier diagnosis, longitudinal monitoring, and translational relevance, the ability to accurately measure Tau in cerebrospinal fluid (CSF), blood, and serum has become increasingly important. This shift places new demands on assay sensitivity, specificity and reproducibility. 

Tau as a Fluid Biomarker

Tau proteins are central to the pathology of Alzheimer’s disease and other neurodegenerative disorders, but they are also biologically complex biomarkers. Their concentrations in fluid samples are typically very low, and their detectability is influenced by multiple variables including:

• Disease stage and progression
• Aging
• Circadian rhythms
• CSF production, turnover and clearance
• Post-translational modifications such as phosphorylation

Unlike imaging-based approaches, fluid biomarkers offer a direct biochemical readout of disease-related processes. However, this advantage comes with a challenges as the most meaningful Tau signals often exist near the lower limits of detection, especially in early or preclinical stages.

Resulting in Tau researchers relying heavily on assays capable of detecting subtle concentration changes while maintaining consistency across samples/timepoints.

The Importance of Sensitivity in Tau Detection

Because Tau and phospho-Tau species are present at picogram-per-millilitre levels, assay sensitivity is not just a “nice to have” - it is cruical. As insufficient sensitivity can obscure relevant differences, limit reproducibility, or prevent detection altogether.

A High-sensitivity Tau ELISA can help researchers to:

• Detect low-abundance Tau proteins with confidence
• Quantify small but meaningful shifts associated with disease onset or progression
• Support longitudinal and translational study designs
• Work across multiple sample types, including CSF, serum and plasma

This is particularly important in CSF-based studies, where Tau concentrations may fluctuate based on diurnal cycles, aging, or disease-related changes in CSF dynamics. Without sufficient sensitivity, these relevant variations can get lost in assay noise.

Total Tau and Phospho-Tau

Not all Tau measurements are equivalent. In addition to Total Tau, phosphorylation-specific Tau species such as Thr181 and Thr231 provide deeper insight and reliable differentiation between these forms requires assays that are both:

• Highly specific - to distinguish phosphorylation states
• Highly sensitive-  to detect low-level signals without cross-reactivity

A Well-designed Tau studys allow researchers to measure both Total Tau and Phospho-Tau in parallel, supporting a more   fuller understanding of the neurodegenerative processes and biomarker trajectories.

Choosing the Right Tools for Tau Research

Given the biological complexity of Tau and the dynamic nature of CSF and blood-based biomarkers, assay performance matters. 

Aviva's New High-performance Tau ELISAs kits allow researchers to:

• Detect low-abundance Total and Phospho-Tau with confidence with 
• Unmatched sensitivity: <2pg/mL for highly specific results
• Quantify subtle molecular changes that precede clinical symptoms
• Reliably measure Tau across complex sample matrices such as CSF, serum and blood

Three option Tau ELISA Kit (Human) (OKGD00201), Phospho-Tau (Thr231) ELISA Kit (OKGD00203) and Phospho-Tau (Thr181) ELISA Kit (OKGD00202)